fludarabine has been researched along with Clinically Isolated CNS Demyelinating Syndrome in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Bejar, J; Garty-Ofir, M; Kreiniz, N; Polliack, A; Tadmor, T | 1 |
| Bertz, H; Bley, TA; Feuerhake, F; Finke, J; Mielke, S; Potthoff, K; Windfuhr, M | 1 |
| Bolgert, F; Camporo, P; Gonzalez, H; Leblond, V | 1 |
3 other study(ies) available for fludarabine and Clinically Isolated CNS Demyelinating Syndrome
| Article | Year |
|---|---|
Demyelinating brain lesions developing in a patient with chronic lymphocytic leukemia shortly after treatment with a fludarabine containing regimen.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Edema; Cyclophosphamide; Demyelinating Diseases; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Rituximab; Steroids; Vidarabine | 2021 |
Fatal leukoencephalopathy after reduced-intensity allogeneic stem cell transplantation.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclosporine; Demyelinating Diseases; Fatal Outcome; Female; Humans; Immunosuppressive Agents; Melphalan; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Risk Assessment; Stem Cell Transplantation; Vidarabine | 2007 |
Progressive multifocal leukoencephalitis (PML) in three patients treated with standard-dose fludarabine (FAMP).
Topics: Antineoplastic Agents; Demyelinating Diseases; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Leukoencephalopathy, Progressive Multifocal; Male; Middle Aged; Neurotoxicity Syndromes; Vidarabine | 1999 |